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Inhibition of the mechano-
enzymatic amyloidogenesis 
of transthyretin: role of ligand 
affinity, binding cooperativity and 
occupancy of the inner channel
Guglielmo Verona1, P. Patrizia Mangione1,2, Sara Raimondi2, Sofia Giorgetti2, Giulia Faravelli2, 
Riccardo Porcari1, Alessandra Corazza1,3, Julian D. Gillmore4, Philip N. Hawkins4, Mark B. 
Pepys1,4, Graham W. Taylor  1 & Vittorio Bellotti  1,2
Dissociation of the native transthyretin (TTR) tetramer is widely accepted as the critical step in TTR 
amyloid fibrillogenesis. It is modelled by exposure of the protein to non-physiological low pH in vitro 
and is inhibited by small molecule compounds, such as the drug tafamidis. We have recently identified 
a new mechano-enzymatic pathway of TTR fibrillogenesis in vitro, catalysed by selective proteolytic 
cleavage, which produces a high yield of genuine amyloid fibrils. This pathway is efficiently inhibited 
only by ligands that occupy both binding sites in TTR. Tolcapone, which is bound with similar high 
affinity in both TTR binding sites without the usual negative cooperativity, is therefore of interest. Here 
we show that TTR fibrillogenesis by the mechano-enzymatic pathway is indeed more potently inhibited 
by tolcapone than by tafamidis but neither, even in large molar excess, completely prevents amyloid 
fibril formation. In contrast, mds84, the prototype of our previously reported bivalent ligand TTR 
‘superstabiliser’ family, is notably more potent than the monovalent ligands and we show here that this 
apparently reflects the critical additional interactions of its linker within the TTR central channel. Our 
findings have major implications for therapeutic approaches in TTR amyloidosis.
The seminal observation that the native non-covalent TTR homotetramer dissociates at low pH into dimers and 
monomers that self-assemble into amyloid fibrils1 is the basis for the current, widely accepted model for TTR 
amyloid formation. However low pH treatment of both wild type and amyloidogenic TTR variants produces 
mostly heterogeneous amorphous aggregates with a very low yield of authentic amyloid fibrils showing pathog-
nomonic green birefringence in polarized light after Congo red staining, characteristic fibrillar electron micro-
scopic appearance and the cross-β X-ray fibre diffraction signature. Ex vivo TTR amyloid deposits, especially 
in the heart, usually contain a substantial proportion of the C-terminal TTR fragment generated by proteolytic 
cleavage at Lys48-Thr49 2. Following this observation we have identified and characterized a novel mechanism of 
TTR amyloid fibrillogenesis mediated by selective tryptic cleavage at residue 48. The highly amyloidogenic TTR 
C-terminal residue 49–127 polypeptide is released, catalysing amyloid fibril formation in vitro, and the whole 
process is strongly enhanced by biomechanical forces3, 4. Abundant authentic amyloid fibrils are produced with 
pathognomonic features indistinguishable from natural ex vivo fibrils.
Compounds able to stabilize TTR, intended for use as drugs to treat and prevent systemic ATTR amyloidosis, 
have hitherto been identified exclusively by their capacity to inhibit TTR dissociation and aggregation induced 
by low pH in vitro. However, we have found that inhibition of the mechano-enzymatic pathway of TTR amyloid 
fibrillogenesis at physiological pH, ionic strength and temperature requires occupation of both thyroxine binding 
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sites in each native TTR tetramer. This is most efficiently achieved by bivalent ligands, exemplified by the palin-
dromic compound mds845, that is spontaneously bound simultaneously and pseudo-irreversibly in both sites. 
Sant’Anna and colleagues6 have recently reported that tolcapone is a potent inhibitor of TTR dissociation and 
aggregation under denaturing conditions. They attribute its efficacy to occupation of both binding pockets with 
similar high affinity in contrast to the notable negative cooperativity observed with thyroxine itself and other 
monovalent ligands, including the TTR stabiliser drugs, tafamidis7, 8 and diflunisal9, which are now in clinical use. 
This important observation prompted us to test the capacity of tolcapone to inhibit mechano-enzymatic amyloi-
dogenesis of TTR using the V122I variant which is the most prevalent cause of hereditary cardiac amyloidosis10.
Results and Discussion
We compared tolcapone with tafamidis7, 8 and the experimental bifunctional compound, mds845 (Fig. 1A). When 
stirred with V122I TTR at 37 °C in PBS in the presence and absence of trypsin for 96 h, all three ligands inhibited 
proteolytic cleavage of the protein in a dose-dependent manner (Fig. 1B and Supplementary Fig. 1). At molar 
Figure 1. Comparative effect of tolcapone on proteolysis and fibrillogenesis of V122I TTR. (A) Chemical 
structures of tolcapone and tafamidis together with the TTR binding palindromic ligand, mds84.  
(B) Aggregation of 18 µM V122I TTR in the presence of 0, 9, 18, 36 and 72 µM of tolcapone, tafamidis and 
mds84 respectively in PBS pH 7.4 at 37 °C with fluid agitation was carried out after addition of trypsin at an 
enzyme:substrate ratio of 1:200. Selective proteolytic cleavage was monitored at 96 h by SDS-PAGE under 
reducing conditions (Supplementary Fig. S1). Intensities of the electrophoretic bands corresponding to 
the intact protomer in the whole mixture were normalized to 100% for the same band of the protein before 
addition of trypsin. The solid lines represent the nonlinear fit to the experimental mean (SD) of three replicates 
using GraphPad Prism v5. Two way ANOVA gave a P value < 0.001 for tafamidis vs mds84 at 9 and 18 µM; 
for tolcapone vs mds84 at 9 µM. (C) Aggregation of 18 µM V122I TTR was quantified as spectrophotometric 
turbidity at 400 nm normalized to 100% for aggregation of the protein in the absence of ligands. We know from 
previous work that TTR aggregation in this system is in the form of authentic amyloid fibrils3, 4. All data shown 
represent mean (SD) of three independent experiments, and *** represents P < 0.001.
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 182  | DOI:10.1038/s41598-017-00338-x
ratios of ligand:TTR tetramer higher than 2:1, the three compounds had similar efficacy with apparent almost 
complete inhibition of TTR cleavage. However at lower molar ratios, mds84 was the most potent inhibitor, fol-
lowed by tolcapone and tafamidis.
Consistent with their inhibition of proteolytic TTR cleavage, the three compounds also inhibited fibril forma-
tion (Fig. 1C). At a ligand:TTR tetramer molar ratio of 0.5:1, mds84 and tolcapone reduced fibril formation by 
approximately 90% and 60% respectively, and tafamidis only by 40%. At molar equivalence, inhibition increased 
at 60% with tafamidis, ~80% with tolcapone and remained at ~90% with mds84. At twofold and greater molar 
excess of ligand, both monovalent ligands, tafamidis and tolcapone inhibited TTR fibrillogenesis by the same 
amount (~90%) as mds84.
Even when we compared the effect of the three compounds on the inhibition of TTR acidic-mediated aggre-
gation11, mds84 at equimolar concentration with TTR was the only ligand able to completely inhibit the process 
(Supplementary Information and Supplementary Fig. S2).
The inhibition of the mechano-enzymatic pathway of TTR amyloidogenesis, which we believe to be the most 
likely pathophysiological mechanism in vivo, depends on the occupation of both thyroxine binding sites. The 
superior potency of tolcapone among monovalent TTR ligands is consistent with its unique property of not 
inducing negative cooperativity6.
The much more effective inhibition of proteolysis-mediated TTR fibrillogenesis by mds84 results from the 
simultaneous occupation of both thyroxine binding sites, and the internal channel between them, by this palin-
dromic molecule5. It occurs rapidly and completely at equimolar concentrations of TTR and ligand. Binding of 
mds84 by native TTR is pseudo-irreversible under physiological conditions5 and generates a stable complex. This 
in contrast to the reversible monovalent ligands for which a higher molar excess is required to saturate both bind-
ing sites in vivo. These limitations on efficacy against mechano-enzymatic mediated amyloidogenesis may explain 
the modest therapeutic benefit of monovalent ligands in the clinical studies reported so far12.
To understand the superior inhibitory effect of bivalent ligands, we analysed the deposited X-ray structures 
of TTR complexed with monovalent ligands, tolcapone6 and tafamidis7, (Fig. 2) in comparison with bivalent 
ligands, mds845 and compounds 20 and 22 of Green et al.13 (Supplementary Fig. S3). For a general description 
of the crystal structures we refer to a very exhaustive review by Palaninathan14. There is no PDB structure of 
the mds84-V122I TTR complex so the analysis is restricted to wild type TTR. This choice is justified by the 
almost perfect superposition of the wild type and V122I TTR structures in the absence of ligands (Supplementary 
Fig. S4A,B) with minor deviations when bound to tolcapone (Supplementary Fig. S4C,D). The average root mean 
square deviations (rmsd) for the TTR backbone residues are 0.45 and 0.9 Å for the two proteins in their free and 
bound form, respectively. Moreover, Val122 and Ile122 side chains point towards the external part of the pocket 
cavity and residue 122 is not present in the halogen binding pockets (HBPs; see Methods). Importantly, neither 
mono- nor bivalent molecules induce major rearrangements of the HBP residues with rmsd values calculated 
for the backbone atoms of HBP1, HBP2 and HBP3 ranging from 0.2 to 0.3 Å (Table 1). The superposition of the 
binding pockets of TTR with and without ligands is shown in Supplementary Fig. S5. Also there is no correlation 
between the number of ligand-protein hydrogen bonds, (Table 1) and inhibitory efficacy. A full list of hydrogen 
bonds between the ligand and the HBPs is reported in the Supplementary Information. However, in contrast with 
the monovalent ligands which interact only with the ligand pocket itself, the methylene linker of the bivalent 
compounds occupies the narrow TTR inner channel with an interaction surface increased by 48 Å2, for mds84 
compared with tolcapone. Binding of mds845, compound 20 and compound 2213 by TTR creates, respectively, 
up to 9, 5 and 4 hydrophobic interactions, mainly with S117 Cβ and Leu110 Cδ2. These interactions make an 
estimated favourable energetic contribution of −4.6, −2.5 and −1.0 kcal/mol for the three ligands respectively. 
Occupancy of the central channel of TTR, estimated for mds84 to be around 80% of the void volume, may thus 
have a crucial role in preventing subunit sliding and also provide long distance stabilisation affecting the dynam-
ics of CD loop, the selective cleavage of which potently primes amyloid fibrillogenesis. The pioneering study 
of Green et al.13 identified the enhanced stabilisation of TTR by bivalent ligands with a central linker but their 
compounds did not interact with native TTR. They were bound only by renaturation of dissociated denatured 
TTR around the ligand.13 In sharp contrast, both the mds84 prototype and its analogues are rapidly bound by 
the native TTR tetramer, traversing the inner channel to occupy it with the linker.5 The unique total binding site 
in TTR, comprising the two halogen binding pockets and the inner channel, is entered by these ligands with a 
decreased entropic cost compared to all monovalent ligands15. The key factors responsible for the ‘superstabiliser’ 
property of mds84 and its analogues are thus likely to be the combination of entropic gain, increased hydrophobic 
contributions of the linker and a reduced void volume in the interface cavity.
The mechanism of binding of TTR by bivalent compounds cannot be fully clarified on the basis of the avail-
able crystallographic structures. These data reveal that the TTR inner cavity is very narrow and therefore appar-
ently inaccessible to the bulky groups of the ligands. We hypothesize that the tetramer dynamics may be larger 
than expected and current studies in our laboratory using NMR might shed light on this important issue.
Finally, even at large molar excess of tafamidis or tolcapone that inhibited obvious in vitro aggregation, ultracen-
trifugation of the reaction mixture yielded a small amount of insoluble material which stained with Congo red to give 
typical green birefringence (Fig. 3A and Supplementary Fig. S6) and was fibrillar in the electron microscope (Fig. 3B). 
In the presence of mds84 such insoluble material was minimal but extensive searching by electron microscopy revealed 
some fibrils (Fig. 3B). Evidently, the mechano-enzymatic mechanism enables slow formation of some fibrils even when 
both binding sites are fully occupied in most TTR molecules. Effective targeting of all TTR molecules with stabilizer 
drugs is much more challenging in vivo than in vitro and it is therefore crucial to consider the significant pathogenic 
impact of even minimal amyloid fibril formation in vivo. There are potentially major implications, that should not be 
ignored, both for interpretation of current clinical studies in TTR amyloidosis and for the design of future therapeutic 
approaches such as the exploitation of non-natural peptides inhibitors of TTR aggregation16 or antibodies recognizing 
cryptic epitope exposed only on the surface of aggregated TTR and not in the native tetrameric state17.
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Figure 2. TTR binding sites in the presence of tolcapone and mds84. Wild type TTR binding sites occupied 
by tolcapone (A) and mds84 (B) with ligands shown as solvent accessible surfaces. For clarity, H2O oxygens are 
shown as spheres with 50% of the van der Waals radius. (C) Wild type TTR-mds84 complex with highlighted 
distances of the principal hydrophobic contacts between the ligand methylene linker and TTR atoms.
Protein (PDB code) *Rmsd (Å)
**Numbers of H 
bonds
WT TTR/tolcapone 
(4d7b) 0.247 3
WT TTR/tafamidis (3tct) 0.196 0
WT TTR/mds84 (3ipe) 0.173 2
WT TTR/compound 20 
(2fbr) 0.298 6
WT TTR/compound 22 
(2flm) 0.319 0
Table 1. Structural comparisons of TTR halogen binding pockets with and without ligands. *The root mean 
square deviation was calculated for the backbone atoms of all the three HBPs for the wild type TTR complexes 
compared to the same protein without ligand (PDB 1dvq). **The hydrogen bonds considered are those between 
the ligand and the HBPs atoms including crystallographic water molecules.
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Methods
Expression of recombinant TTR. V122I TTR was expressed using a pET3a vector containing the full-length 
cDNA for human V122I TTR in E. coli BL21 super competent cells. Expression colonies were grown to an optical 
density at 600 nm of 1.0 in Luria-Bertani broth containing 100 µg ml−1 ampicillin at 37 °C; protein synthesis was 
induced with 1 mM isopropyl-β-D-thiogalactoside at 18 °C overnight. The following day cells were harvested by 
centrifugation at 2,150 g for 30 min, the pellet was suspended in buffer containing 25 mM Tris-HCl, 2 mM EDTA, 
0.1% Triton, pH 7.4 and sonicated at 12 μm amplitude for 10 cycles (1 min on/1 min off). The intracellular proteins 
were fractionated by 2 cycles of ammonium sulphate precipitation. TTR, which precipitated between 30 and 60% 
ammonium sulphate, was dissolved in 25 mM Tris-HCl, 0.1 M NaCl, pH 8.0 and fractionated on a Superdex 75 
Hi Load 26/60 gel filtration column (GE Healthcare Life Science) equilibrated and eluted in the same buffer. TTR 
enriched fractions were dialyzed overnight against 25 mM Tris-HCl, pH 8.0, reduced with dithiothreitol and then 
applied to a Q-Sepharose anion exchange column equilibrated in 25 mM Tris-HCl pH 8.0 and eluted with a linear 
0–1 M NaCl gradient in the same solvent. TTR enriched fractions were pooled, concentrated and further purified 
on the Superdex 75 Hi Load 26/60 column. Fractions containing TTR were dialyzed against water at 4 C for at least 
3 days and then lyophilized. Purity was confirmed by SDS-PAGE and electrospray ionisation mass spectrometry.
Fibrillogenesis of V122I TTR in the presence of ligands. Fibrillogenesis experiments were performed 
in standard glass vials stirred at 1,500 r.p.m. (IKA magnetic stirrer) at 37 °C using 1 mg ml−1 of V122I TTR (18 µM 
tetramer) in PBS at pH 7.4 in the presence and in the absence (control) of 5 ng µl−1 of trypsin. Tolcapone, tafa-
midis and mds84 were dissolved individually at 10 mM in DMSO, followed by serial dilutions which, when added 
in appropriate volume to TTR, provided ligand:TTR tetramer molar ratios of 0.5:1, 1:1, 2:1 and 4:1 respectively. 
Turbidity at 400 nm was used to monitor fibril formation over time until it reached a plateau at 96 h. The thio-
flavin T assay18 could not be used because tolcapone and mds84 interfere with the fluorescence measurement. 
At the end of the aggregation, susceptibility to trypsin was monitored using SDS-homogeneous 15% PAGE (GE 
Healthcare) under reducing conditions. Two-way Anova was performed using GraphPad Prism 5 for pairwise 
multiple comparison among tafamidis, tolcapone and mds84.
Figure 3. Residual amyloid aggregates in the presence of excess of ligands. (A) Congo-red stained specimens 
viewed under intense cross polarized light in the absence of any ligands and in the presence of fourfold molar 
excess of mds84, tolcapone and tafamidis (Supplementary Fig. S6). Some fragments of amyloid are present with 
maximally inhibitory ligand concentrations (Fig. 1), although least with mds84. Scale bar, 100 µM. (B) Typical 
fibrillar structures detected by exhaustive analysis of negatively stained electron microscopy images of the same 
TTR-ligand preparations. Scale bar, 100 nm.
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The pellet was harvested from each protein sample in the absence and in the presence of ligands by ultra-
centrifugation in a Beckman Optima TL ultracentrifuge at 135,000 g, 20 min. After resuspension of the pellet 
with a minimal volume of PBS, samples were stained with alkaline alcoholic Congo red and examined by high 
intensity cross polarized light microscopy19. Amyloid load was scored in the Congo red stained pellet of TTR in 
the presence of fourfold molar excess of each ligand (Supplementary Fig. S6). A blind quantification was carried 
out by an expert operator on six slides per each group of treatment using the following grading score: 0 (no spot 
detected), 1 (occasional spots), 2 (green birefringent spots clearly visible and corresponding to the stained mate-
rial in the bright field), 3 (surface homogeneously covered by green birefringent material). The non-parametric 
Kruskall-Wallis test for mds84 vs tafamidis (or tolcapone) was applied using GraphPad Prism 5.
Samples were also examined by negative staining transmission electron microscopy. Briefly, a drop of each 
sample was allowed to dry on formvar coated copper EM grids for 2 min before blotting with filter paper to 
remove excess solvent and staining with 2% w/v uranyl acetate for 1 min. After further blotting and drying in air, 
transmission electron microscope (Jeol1200EX) images were obtained at 80 kV.
Structural analysis. X-ray structures of wild type TTR alone (PDP codes 1DVQ and 5CN3) and complexed with 
tolcapone, tafamidis, mds84, compound 20 and 22 (PDB codes 4D7B, 3TCT, 3IPE, 2FBR and 2FLM, respectively) 
were examined using VMD, SPDBV20, 21 and Pymol (PyMOL Molecular Graphics System, Version 1.8 Schrödinger, 
LLC). The energetic contribution of the linker to the binding was estimated by the SeeSAR programme (https://www.
biosolveit.de/SeeSAR). The halogen binding pockets considered in the analysis are formed by Met13, Lys15, Leu17, 
Thr106, Ala108, Val121 (HBP1); Lys17, Ala108, Ala109, Leu110 (HBP2); Ala108, Ser117, Leu110, Thr119 (HBP3).
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